The treatment landscape for gynaecological cancers, especially ovarian cancer, has evolved over recent years. Late diagnosis means ovarian cancer is often detected at an advanced stage, but the introduction of targeted therapies and immunotherapies have widened the treatment landscape. Cervical cancer has a high survival rate if detected early, and therefore screening continues to be an important issue.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.”
Our supporting partners do not constitute an endorsement of the content on this page.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Two experts discuss evolving immunotherapy standards of care in advanced/recurrent endometrial cancer.
Watch two experts discuss HPV-related disease, vaccination scheduling and strategies to increase uptake.
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
Hear expert insights on the role of immunotherapy in treating advanced/recurrent endometrial cancer.
Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...
The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1Â Platinum-based chemotherapy had long been the standard of care in ...
Experts share key guideline recommendations and safety considerations for systemic treatment options.
Select a discussion in the hub to watch our multidisciplinary team share expert perspectives on the appropriate implementation of immune checkpoint inhibitors through shared decision making to ensure optimal outcomes for patients with endometrial cancer.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.